GSDMD and atrial fibrillation: Further research investigating the clinical utility of experimental targeted treatment on the NLRP3 inflammasome e.g., MCC950, dapansutrile, RRx-001, DFV890, Bay 11-7082, Βeta-hydroxybutyrate, usnoflast, ibrutinib, and CY-09, or drugs targeting crucial checkpoints of the NLRP3 inflammasome-pathway e.g., Caspase-1 inhibitors (VX-765 and VX-740) or GSDMD inhibitors (disulfiram and necrosulfonamide), might potentially bring hope for the better management of AF.